McAuliffe P F, Hall M J, Castro-Malaspina H, Heinemann M H
Department of Ophthalmology, New York Hospital, Cornell Medical Center, NY 10021, USA.
Am J Ophthalmol. 1997 May;123(5):702-3. doi: 10.1016/s0002-9394(14)71090-6.
To report a case in which we treated cytomegalovirus retinitis using an intravitreal ganciclovir sustained-release device in a patient negative for the human immunodeficiency virus, with a history of myeloproliferative syndrome with myelofibrosis and profound immunosuppression after allogeneic bone marrow transplantation.
Case report. Review of medical records and fundus photographs.
After the ganciclovir device was implanted, the cytomegalovirus retinitis did not progress, and visual acuity improved. We removed the device 9 months after implantation.
The ganciclovir sustained-release device may be useful for treating cytomegalovirus retinitis in patients without the acquired immunodeficiency syndrome who are profoundly immunosuppressed and fail conventional intravenous therapy. If immune suppression is of limited duration, the device can be removed.
报告1例使用更昔洛韦玻璃体内缓释装置治疗巨细胞病毒性视网膜炎的病例，该患者人类免疫缺陷病毒阴性，有骨髓增殖综合征伴骨髓纤维化病史，且在异基因骨髓移植后出现严重免疫抑制。
病例报告。回顾病历和眼底照片。
植入更昔洛韦装置后，巨细胞病毒性视网膜炎未进展，视力提高。植入9个月后取出该装置。
更昔洛韦缓释装置可能有助于治疗无获得性免疫缺陷综合征但存在严重免疫抑制且常规静脉治疗无效的巨细胞病毒性视网膜炎患者。如果免疫抑制持续时间有限，可取出该装置。
